Results
|
1541.
|
|
|
1542.
|
|
|
1543.
|
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. [electronic resource] by
- Mazières, Julien
- Peters, Solange
- Lepage, Benoit
- Cortot, Alexis B
- Barlesi, Fabrice
- Beau-Faller, Michéle
- Besse, Benjamin
- Blons, Hélène
- Mansuet-Lupo, Audrey
- Urban, Thierry
- Moro-Sibilot, Denis
- Dansin, Eric
- Chouaid, Christos
- Wislez, Marie
- Diebold, Joachim
- Felip, Enriqueta
- Rouquette, Isabelle
- Milia, Julie D
- Gautschi, Oliver
Producer: 20130726
In:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 31
Availability: No items available.
|
|
1544.
|
|
|
1545.
|
Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients. [electronic resource] by
- Arslan, U Y
- Turker, I
- Aksoy, S
- Oksuzoglu, B
- Helvaci, K
- Yildirim Ozdemir, N
- Uyeturk, U
- Uysal Sonmez, O
- Budakoglu, B
- Zengin, N
Producer: 20140211
In:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology vol. 18
Availability: No items available.
|
|
1546.
|
|
|
1547.
|
|
|
1548.
|
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. [electronic resource] by
- Weroha, S John
- Oberg, Ann L
- Ziegler, Katie L Allen
- Dakhilm, Shaker R
- Rowland, Kendrith M
- Hartmann, Lynn C
- Moore, Dennis F
- Keeney, Gary L
- Peethambaram, Prema P
- Haluska, Paul
Producer: 20110725
In:
Gynecologic oncology vol. 122
Availability: No items available.
|
|
1549.
|
|
|
1550.
|
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. [electronic resource] by
- Kurokawa, Manabu
- Kim, Jiyeon
- Geradts, Joseph
- Matsuura, Kenkyo
- Liu, Liu
- Ran, Xu
- Xia, Wenle
- Ribar, Thomas J
- Henao, Ricardo
- Dewhirst, Mark W
- Kim, Wun-Jae
- Lucas, Joseph E
- Wang, Shaomeng
- Spector, Neil L
- Kornbluth, Sally
Producer: 20131209
In:
Science signaling vol. 6
Availability: No items available.
|
|
1551.
|
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. [electronic resource] by
- Müller, Volkmar
- Gade, Stephan
- Steinbach, Bettina
- Loibl, Sibylle
- von Minckwitz, Gunter
- Untch, Michael
- Schwedler, Kathrin
- Lübbe, Kristina
- Schem, Christian
- Fasching, Peter A
- Mau, Christine
- Pantel, Klaus
- Schwarzenbach, Heidi
Producer: 20150921
In:
Breast cancer research and treatment vol. 147
Availability: No items available.
|
|
1552.
|
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. [electronic resource] by
- Wang, Leiping
- Zhang, Qunling
- Zhang, Jian
- Sun, Si
- Guo, Haiyi
- Jia, Zhen
- Wang, Biyun
- Shao, Zhimin
- Wang, Zhonghua
- Hu, Xichun
Producer: 20111031
In:
BMC cancer vol. 11
Availability: No items available.
|
|
1553.
|
Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. [electronic resource] by
- Li, Jixia
- Zhu, Feng
- Lubet, Ronald A
- De Luca, Antonella
- Grubbs, Clinton
- Ericson, Marna E
- D'Alessio, Amelia
- Normanno, Nicola
- Dong, Zigang
- Bode, Ann M
Producer: 20130415
In:
Molecular carcinogenesis vol. 52
Availability: No items available.
|
|
1554.
|
|
|
1555.
|
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. [electronic resource] by
- Rhee, Jiyoung
- Han, Sae-Won
- Cha, Yongjun
- Ham, Hye Seon
- Kim, Hwang-phill
- Oh, Do-Youn
- Im, Seock-Ah
- Park, Jong-Wan
- Ro, Jungsil
- Lee, Keun Seok
- Park, In Hae
- Im, Young-Hyuck
- Bang, Yung-Jue
- Kim, Tae-You
Producer: 20110321
In:
Breast cancer research and treatment vol. 125
Availability: No items available.
|
|
1556.
|
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. [electronic resource] by
- Diéras, Véronique
- Miles, David
- Verma, Sunil
- Pegram, Mark
- Welslau, Manfred
- Baselga, José
- Krop, Ian E
- Blackwell, Kim
- Hoersch, Silke
- Xu, Jin
- Green, Marjorie
- Gianni, Luca
Producer: 20170824
In:
The Lancet. Oncology vol. 18
Availability: No items available.
|
|
1557.
|
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. [electronic resource] by
- Dang, Chau
- Lin, Nancy
- Moy, Beverly
- Come, Steven
- Sugarman, Steven
- Morris, Patrick
- Abbruzzi, Alyson
- Chen, Carol
- Steingart, Richard
- Patil, Sujata
- Norton, Larry
- Winer, Eric
- Hudis, Clifford
Producer: 20100706
In:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 28
Availability: No items available.
|
|
1558.
|
hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer. [electronic resource] by
- Wittinger, Michael
- Vanhara, Petr
- El-Gazzar, Ahmed
- Savarese-Brenner, Bettina
- Pils, Dietmar
- Anees, Mariam
- Grunt, Thomas W
- Sibilia, Maria
- Holcmann, Martin
- Horvat, Reinhard
- Schemper, Michael
- Zeillinger, Robert
- Schöfer, Christian
- Dolznig, Helmut
- Horak, Peter
- Krainer, Michael
Producer: 20120611
In:
Clinical cancer research : an official journal of the American Association for Cancer Research vol. 17
Availability: No items available.
|
|
1559.
|
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. [electronic resource] by
- Mimura, Kousaku
- Shiraishi, Kensuke
- Mueller, Anja
- Izawa, Shinichiro
- Kua, Ley-Fang
- So, Jimmy
- Yong, Wei-Peng
- Fujii, Hideki
- Seliger, Barbara
- Kiessling, Rolf
- Kono, Koji
Producer: 20140218
In:
Journal of immunology (Baltimore, Md. : 1950) vol. 191
Availability: No items available.
|
|
1560.
|
|